- Home
- PAYS vs AVTX Comparison
PAYS vs AVTX Comparison
Compare PAYS & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PAYS | AVTX |
|---|---|---|
| Founded | 2001 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.4M | 248.3M |
| IPO Year | 1998 | 2015 |
Fundamental Metrics
Financial Performance| Metric | PAYS | AVTX |
|---|---|---|
| Price | $3.40 | $15.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $8.06 | ★ $34.50 |
| AVG Volume (30 Days) | 381.5K | ★ 387.9K |
| Earning Date | 03-24-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $74,879,428.00 | $192,000.00 |
| Revenue This Year | $41.20 | N/A |
| Revenue Next Year | $20.62 | N/A |
| P/E Ratio | $26.04 | ★ N/A |
| Revenue Growth | ★ 32.61 | N/A |
| 52 Week Low | $1.80 | $3.39 |
| 52 Week High | $8.88 | $20.72 |
Technical Indicators
Market Signals| Indicator | PAYS | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 23.19 | 48.70 |
| Support Level | $3.25 | $13.50 |
| Resistance Level | $3.51 | $14.81 |
| Average True Range (ATR) | 0.21 | 1.18 |
| MACD | -0.03 | 0.07 |
| Stochastic Oscillator | 9.21 | 54.79 |
Price Performance
Historical ComparisonAbout PAYS Paysign Inc.
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).